Revvity Launched Signals for Startups to Support Early-Stage Biotechs

22 July 2026 | Wednesday | News

The new program provides enterprise-grade Signals software, guided onboarding, and scalable informatics workflows to help emerging biotech companies accelerate research, improve collaboration, and build a strong digital foundation.

  • Enterprise-grade Signals software with guided onboarding positioned specifically for early-stage biotechs
  • Science-first setup with ready-to-use Signals environments and modality-specific workflows
  • Scalable informatics foundation that supports growth, collaboration and investor readiness

Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies adopt scalable informatics capabilities earlier in their growth journey. Built for early-stage biotechs, the program combines access to enterprise-grade Signals software with guided onboarding and best-practice configurations tailored specifically for smaller biotechs to help accelerate innovation, improve scientific productivity and shorten time-to-value.

Startup biotechs are often under pressure to move quickly with limited IT, informatics and operational resources while managing increasingly complex discovery data. Signals for Startups addresses this challenge with a purpose-built, scalable Signals environment that helps teams focus on science while establishing a strong digital foundation from day one. Out-of-the-box configurations for large and small molecules enable companies to accelerate adoption, standardize data, and enhance collaboration on a proven, scalable informatics infrastructure.

“Signals for Startups addresses a critical need for emerging biotech companies that want to move fast without creating data and workflow challenges that limit their ability to scale,” said Kevin Willoe, president of Revvity Signals Software. “By combining startup-friendly access with guided onboarding and scalable Signals workflows, we are helping early-stage teams build the digital foundation they need to advance discovery, support investor readiness and grow with confidence.”

Signals for Startups offers a structured entry point into the Revvity Signals portfolio with bundled licenses appropriate for startups with a clear path for expansion as companies grow from seed stage through venture investment rounds and beyond. The program is designed to help startups avoid fragmented systems and disconnected data practices that can slow progress, increase rework, and create challenges as research programs mature.

Signals for Startups is expected to be available in the United States and Europe, the Middle East, and Africa in late July 2026.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close